Skip to main content
Premium Trial:

Request an Annual Quote

UK Gene Transfection Firm NanoTherics Closes $1.8M Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – UK gene transfection company NanoTherics announced the close of a £1.1 million ($1.8 million) round, to be used to further commercialize the company's products.

The firm also announced the appointment of David George as chairman.

Catapult Venture Managers, which invested £600,000, and Mercia Technology Seed Fund, which provided £200,000, were the lead investors in the round, with the remaining funds coming from private investors. The round closed in late August, NanoTherics CEO Linda Cammish said.

In a statement, she added that the investment comes at a "key point" in the firm's growth strategy "and will enable us to place additional resources into the commercialization of our products."

The company sells cell transfection devices and related reagents.

Spun out of Keele University in 2007, NanoTherics develops gene transfection products. According to the company's website, its technologies — developed by researchers at Keele University and the University of Florida — use magnetic nanoparticles and oscillating magnetic fields to transfect biomaterials into cells. The technologies, it added, provides "significant performance enhancement" over the best non-viral techniques on the market.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.